*Author Search Results*

sublabel_SolrAuthor

*Authority Data* (*EntityFactsFrom* GND / Entity Facts )

Gesine Bug

*BiographicalDetails*
Oberärztin Hämatologie/Onkologie, Leiterin Forschungslabor AG Bug

*Affiliation*
Universitätsklinikum Frankfurt

More Links

Gemeinsame Normdatei (GND) im Katalog der Deutschen Nationalbibliothek

Open Researcher and Contributor ID (ORCID)

Deutsche Digitale Bibliothek

Virtual International Authority File (VIAF)

First-in-human study of MDG1011, a TCR-T therapy directed against HLA-A*02:01-restricted PRAME antigen for high-risk myeloid and lymphoid neoplasms

Thomas, Simone (Verfasser)

Freiburg : Universität, 2025

*eBook*

Changes in chronic graft-versus-host disease treatment over time: a 15-years survey within allogeneic hematopoietic stem cell transplant centers in Germany, Austria, and Switzerland

Denk, Alexander (Verfasser)

Freiburg : Universität, 2025

*eBook*

Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site

Wiercinska, Eliza (Verfasser)

Journal of translational medicine. - London : BioMed Central, 08.04.2021. - Seite 1-10. - 10.1186/s12967-021-02810-9. - ISSN 1479-5876. - Jahrgang 19, Artikel 145

*eBook*

Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party

Duque Afonso, Jesús (Verfasser)

Freiburg : Universität, 2025

*eBook*

Sensitization of non-M3 acute myeloid leukemia blasts to all-trans retinoic acid by the LSD1 inhibitor tranylcypromine: TRANSATRA phase I study

Kruszewski, Michael (Verfasser)

Freiburg : Universität, 2025

*eBook*

Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial

Hund, Inga (Verfasser)

Freiburg : Universität, 2025

*eBook*

Reducing the red blood cell transfusion threshold from 8·0 g/dl to 7·0 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome

Ballo, Olivier (Verfasser)

Vox sanguinis. - Oxford [u.a.] : Wiley-Blackwell, 1956-. - Online-Ressource. - 10.1111/(ISSN)1423-0410. - ISSN 1423-0410. - Band 115, Heft 7 (2020), Seite 570-578

*eArticle*

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease

Bönig, Halvard (Verfasser)

Freiburg : Universität, 2024

*eBook*

Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: a multi-centre observational study

Hopff, Sina M. (Verfasser)

Freiburg : Universität, 2024

*eBook*

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Bönig, Halvard (Verfasser)

Freiburg : Universität, 2023

*eBook*

Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy : retrospective analysis of changes over 3 yr in a German hospital

Böhme, Angelika

European journal of haematology. - Oxford : Wiley-Blackwell, 1987-. - Online-Ressource. - 10.1111/(ISSN)1600-0609. - ISSN 1600-0609. - Band 88, Heft 1 (2012), Seite 68-77

2011

*eArticle*